{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:39:54Z","timestamp":1788349194372,"version":"build-2803163510"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,7,31]],"date-time":"2021-07-31T00:00:00Z","timestamp":1627689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,31]],"date-time":"2021-07-31T00:00:00Z","timestamp":1627689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s10072-021-05517-3","type":"journal-article","created":{"date-parts":[[2021,7,31]],"date-time":"2021-07-31T04:14:59Z","timestamp":1627704899000},"page":"4789-4792","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Guillain-Barr\u00e9 syndrome and myasthenia gravis in the context of autoimmune polyendocrine syndrome type III"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6709-3489","authenticated-orcid":false,"given":"Marianna Gabriella","family":"Rispoli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Ferri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Ajdinaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeriana","family":"Falzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Di Muzio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,31]]},"reference":[{"issue":"47","key":"5517_CR1","doi-asserted-by":"publisher","first-page":"e18104","DOI":"10.1097\/MD.0000000000018104","volume":"98","author":"Y Cao","year":"2019","unstructured":"Cao Y, Gui M, Ji S, Bu B (2019) Guillain-Barr\u00e9 syndrome associated with myasthenia gravis: Three cases report and a literature review. Medicine. 98(47):e18104","journal-title":"Medicine."},{"issue":"1","key":"5517_CR2","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s13760-019-01102-w","volume":"120","author":"UK Misra","year":"2020","unstructured":"Misra UK, Kalita J, Singh VK, Kumar S (2020) A study of comorbidities in myasthenia gravis. Acta Neurol Belg 120(1):59\u201364","journal-title":"Acta Neurol Belg"},{"issue":"3","key":"5517_CR3","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/S0303-8467(01)00132-9","volume":"103","author":"A Polizzi","year":"2001","unstructured":"Polizzi A, Ruggieri M, Vecchio I, Genovese S, Rampello L, Raffaele R (2001) Autoimmune thyroiditis and acquired demyelinating polyradiculoneuropathy. Clin Neurol Neurosurg 103(3):151\u2013154","journal-title":"Clin Neurol Neurosurg"},{"key":"5517_CR4","doi-asserted-by":"crossref","unstructured":"Pham-Dobor G, Han\u00e1k L, Hegyi P, M\u00e1rta K, P\u00e1rniczky A, Gergics M, et al (2020) Prevalence of other autoimmune diseases in polyglandular autoimmune syndromes type II and III. J Endocrinol Invest 43(9):1\u20139","DOI":"10.1007\/s40618-020-01229-1"},{"issue":"1","key":"5517_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1530\/EJE-09-0044","volume":"161","author":"GJ Kahaly","year":"2009","unstructured":"Kahaly GJ (2009) Polyglandular autoimmune syndromes. Eur J Endocrinol 161(1):11\u201320","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"5517_CR6","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1016\/j.autrev.2016.09.009","volume":"15","author":"P Fallahi","year":"2016","unstructured":"Fallahi P, Ferrari SM, Ruffilli I, Elia G, Biricotti M, Vita R et al (2016) The association of other autoimmune diseases in patients with autoimmune thyroiditis: review of the literature and report of a large series of patients. Autoimmun Rev 15(12):1125\u20131128","journal-title":"Autoimmun Rev"},{"issue":"20","key":"5517_CR7","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1056\/NEJMra030158","volume":"350","author":"GS Eisenbarth","year":"2004","unstructured":"Eisenbarth GS, Gottlieb PA (2004) Autoimmune polyendocrine syndromes. N Engl J Med 350(20):2068\u20132079","journal-title":"N Engl J Med"},{"key":"5517_CR8","doi-asserted-by":"publisher","first-page":"205873922094234","DOI":"10.1177\/2058739220942340","volume":"18","author":"V Di Stefano","year":"2020","unstructured":"Di Stefano V, Barbone F, Ferrante C, Telese R, Vitale M, Onofrj M et al (2020) Inflammatory polyradiculoneuropathies: clinical and immunological aspects, current therapies, and future perspectives. European Journal of Inflammation 18:2058739220942340","journal-title":"European Journal of Inflammation"},{"key":"5517_CR9","doi-asserted-by":"publisher","first-page":"116648","DOI":"10.1016\/j.jns.2019.116648","volume":"410","author":"J Morren","year":"2020","unstructured":"Morren J, Li Y (2020) Maintenance immunosuppression in myasthenia gravis, an update. J Neurol Sci. 410:116648","journal-title":"J Neurol Sci."},{"issue":"11","key":"5517_CR10","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1212\/WNL.41.11.1848","volume":"41","author":"B Carlander","year":"1991","unstructured":"Carlander B, Touchon J, Georgesco M, Cadilhac J (1991) Myasthenia gravis and recurrent Guillain-Barr\u00e9 syndrome. Neurology. 41(11):1848","journal-title":"Neurology."},{"issue":"6","key":"5517_CR11","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1002\/mus.21466","volume":"40","author":"NK Briscoe","year":"2009","unstructured":"Briscoe NK, Mezei MM (2009) Polyglandular autoimmune syndrome type 3 in a patient with ocular myasthenia gravis. Muscle Nerve 40(6):1064","journal-title":"Muscle Nerve"},{"issue":"3","key":"5517_CR12","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s10072-011-0579-3","volume":"32","author":"JY Wang","year":"2011","unstructured":"Wang JY, Pan J, Luo BY, Zhang YY (2011) Temporal coincidence of myasthenia gravis and Guillain Barr\u00e9 syndrome associated with Hashimoto thyroiditis. Neurol Sci 32(3):515","journal-title":"Neurol Sci"},{"key":"5517_CR13","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.12659\/AJCR.918996","volume":"20","author":"M Gobaru","year":"2019","unstructured":"Gobaru M, Ashida K, Yoshinobu S, Nagayama A, Kabashima M, Iwata S et al (2019) Human Leukocyte Antigen (HLA) Subtype-dependent development of myasthenia gravis, type-1 diabetes mellitus, and Hashimoto disease: a case report of autoimmune polyendocrine syndrome type 3. The American journal of case reports 20:1709","journal-title":"The American journal of case reports"},{"issue":"2","key":"5517_CR14","first-page":"438","volume":"82","author":"M Marin\u00f3","year":"1997","unstructured":"Marin\u00f3 M, Ricciardi R, Pinchera A, Barbesino G, Manetti L, Chiovato L et al (1997) Mild clinical expression of myasthenia gravis associated with autoimmune thyroid diseases. J Clin Endocrinol Metab 82(2):438\u2013443","journal-title":"J Clin Endocrinol Metab"},{"key":"5517_CR15","doi-asserted-by":"crossref","unstructured":"Bowley MP, Chad DA (2019) Clinical neurophysiology of demyelinating polyneuropathy. Handbook of clinical neurology, 161. Elsevier pp 241\u2013268","DOI":"10.1016\/B978-0-444-64142-7.00052-7"},{"issue":"4","key":"5517_CR16","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1507\/endocrj.EJ16-0418","volume":"64","author":"MM Yalcin","year":"2017","unstructured":"Yalcin MM, Altinova AE, Cavnar B, Bolayir B, Akturk M, Arslan E et al (2017) Is thyroid autoimmunity itself associated with psychological well-being in euthyroid Hashimoto\u2019s thyroiditis? Endocr J 64(4):425\u2013429","journal-title":"Endocr J"},{"issue":"6","key":"5517_CR17","doi-asserted-by":"publisher","first-page":"779","DOI":"10.2337\/diab.38.6.779","volume":"38","author":"JJ Cook","year":"1989","unstructured":"Cook JJ, Hudson I, Harrison LC, Dean B, Colman PG, Werther G et al (1989) Double-blind controlled trial of azathioprine in children with newly diagnosed type I diabetes. Diabetes 38(6):779\u2013783","journal-title":"Diabetes"},{"issue":"10","key":"5517_CR18","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJM198809083191002","volume":"319","author":"J Silverstein","year":"1988","unstructured":"Silverstein J, Maclaren N, Riley W, Spillar R, Radjenovic D, Johnson S (1988) Immunosuppression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus. N Engl J Med 319(10):599\u2013604","journal-title":"N Engl J Med"},{"issue":"3","key":"5517_CR19","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1080\/09546630600791442","volume":"17","author":"M Radmanesh","year":"2006","unstructured":"Radmanesh M, Saedi K (2006) The efficacy of combined PUVA and low-dose azathioprine for early and enhanced repigmentation in vitiligo patients. J Dermatol Treat 17(3):151\u2013153","journal-title":"J Dermatol Treat"},{"issue":"11","key":"5517_CR20","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1002\/ccr3.1827","volume":"6","author":"MM Allam","year":"2018","unstructured":"Allam MM, Elzawawy HTH (2018) Induction of remission in autoimmune polyglandular syndrome type three (APS III): an old drug with new perspectives. Clinical case reports 6(11):2178","journal-title":"Clinical case reports"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-021-05517-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-021-05517-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-021-05517-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,16]],"date-time":"2021-10-16T13:33:13Z","timestamp":1634391193000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-021-05517-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,31]]},"references-count":20,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["5517"],"URL":"https:\/\/doi.org\/10.1007\/s10072-021-05517-3","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,31]]},"assertion":[{"value":"22 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Obtained.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent for publication"}},{"value":"Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data sharing statement"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}